Mr Peter Mullen

Research Fellow

Researcher profile

Phone

+44 (0)1334 46 3510

Email

pm72@st-andrews.ac.uk

 

Research areas

I am a Research Fellow working with Professor David Harrison.  My current research interests are in establishing primary tumouroids from both renal and colorectal cancers using fresh tissue obtained from patients undergoing surgery.  Methodolgy includes the use spinner flasks and / or microfluidic devices to establish 3D cultures (tumouroids) which, after treatment with either conventional or protide-modified drugs, can be collected and analysed by conventional techniques including immunofluorescence (IF).

Selected publications

• Open access

  A phosphoramidate modification of FUDR, NUC-3373, causes DNA damage and DAMPs release from colorectal cancer cells, potentiating lymphocyte-induced cell death

  Read, O., Bre, J., Zhang, Y., Mullen, P., Elshani, M. & Harrison, D., 16 Sept 2025, In: PLoS One. 20, 9, p. 1-19 19 p., e0331567.

  Research output: Contribution to journal › Article › peer-review

• Open access

  Kidney tumoroid characterisation by spatial mass spectrometry with same-section multiplex immunofluorescence uncovers tumour microenvironment lipid signatures associated with aggressive tumour phenotypes

  Abdullah, H., Zickuhr, G. M., Um, I. H., Laird, A., Mullen, P., Harrison, D. J. & Dickson, A. L., 16 Sept 2025, In: npj Imaging. 3, p. 1-11 11 p., 43.

  Research output: Contribution to journal › Article › peer-review

• Open access

  Defining the mode of action of cisplatin combined with NUC-1031, a phosphoramidate modification of gemcitabine

  Patel, D., Dickson, A., Zickuhr, G. M., Um, I. H., Read, O. J., Melo Czekster, C., Mullen, P., Harrison, D. J. & Bre, J. L., 1 Dec 2024, In: Translational Oncology. 50, 11 p., 102114.

  Research output: Contribution to journal › Article › peer-review

• Open access

  The novel anti-cancer fluoropyrimidine NUC-3373 is a potent inhibitor of thymidylate synthase and an effective DNA-damaging agent

  Bré, J. L., Dickson, A., Read, O. J., Zhang, Y., McKissock, F. G., Mullen, P., Tang, P., Zickuhr, G. M., Melo Czekster, C. & Harrison, D. J., 31 Mar 2023, In: Cancer Chemotherapy and Pharmacology. 12 p.

  Research output: Contribution to journal › Article › peer-review

• Open access

  Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα and cell-cycle signaling in a breast cancer model

  Moore, K. M., Cerqueira, V., MacLeod, K. G., Mullen, P., Hayward, R. L., Green, S., Harrison, D. J., Cameron, D. A. & Langdon, S. P., 28 Feb 2022, (E-pub ahead of print) In: Exploration of Targeted Anti-tumor Therapy. 3, p. 97-116 20 p.

  Research output: Contribution to journal › Article › peer-review

• Open access

  Genome-scale CRISPR/Cas9 screen determines factors modulating sensitivity to ProTide NUC-1031

  Sarr, A., Bré, J., Um, I. H., Chan, T. H., Mullen, P., Harrison, D. J. & Reynolds, P. A., 21 May 2019, In: Scientific Reports. 9, 13 p., 7643.

  Research output: Contribution to journal › Article › peer-review

• Open access

  A signaling visualization toolkit to support rational design of combination therapies and biomarker discovery: SiViT

  Brown, J. L., Shovman, M., Robertson, P., Boiko, A., Goltsov, A., Mullen, P. & Harrison, D. J., May 2017, In: Oncotarget. 8, 18, p. 29657-29667 11 p.

  Research output: Contribution to journal › Article › peer-review

• Open access

  Inhibition of pH regulation as a therapeutic strategy in hypoxic human breast cancer cells

  Meehan, J., Ward, C., Turnbull, A., Bukowski-Wills, J., Finch, A., Jarman, E. J., Xintaropoulou, C., Martinez-Perez, C., Gray, M., Pearson, M., Mullen, P., Supuran, C. T., Carta, F., Harrison, D. J., Kunkler, I. H. & Langdon, S., 2017, In: Oncotarget. 8, 26, p. 42857-42875

  Research output: Contribution to journal › Article › peer-review

• Open access

  Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: a case study in advanced kidney cancer

  Lubbock, A. L. R., Stewart, G. D., O'Mahoney, F. C., Laird, A., Mullen, P., O'Donnell, M., Powles, T., Harrison, D. J. & Overton, I. M., 26 Jun 2017, In: BMC Medicine. 15, 12 p., 118.

  Research output: Contribution to journal › Article › peer-review

• Open access

  Antitumour activity of the novel flavonoid oncamex in preclinical breast cancer models

  Martínez-Pérez, C., Ward, C., Turnbull, A. K., Mullen, P., Cook, G., Meehan, J., Jarman, E. J., Thomson, P. I. T., Campbell, C. J., McPhail, D., Harrison, D. J. & Langdon, S. P., 13 Apr 2016, In: British Journal of Cancer. 114, 8, p. 905-916

  Research output: Contribution to journal › Article › peer-review

 

See more publications